Authors' objectives:

To determine whether BTX-A, as compared to other interventions, is efficacious and safe when it is used by patients with upper and lower limb spasticity.

Authors' recommendations: BTX-A decreases muscle tone across most disease states. Increased range of motion, improved gait and improved function occur in many studies. Statistical significance is not always reached. The variability across studies may be a result of the variety of disorders studied and their unique expression; and differences in outcome measures and study design. Combining the results to improve clarity is sometimes impossible. The adverse events reported in most trials are low in number and often temporary. Improved methods of reporting, however, would allow for more robust conclusions about the comparative safety of BTX-A. Long-term patient-specific goal-focused outcomes are needed to further define clinically meaningful improvements in therapeutic outcomes.

Authors' methods: Systematic review

Project Status: Completed

URL for project: https://www.ccohta.ca/

Year Published: 2005

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Canadian Coordinating Office for Health Technology Assessment

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)